Generic name
Amitriptyline: adverse event reports filed with FDA
16,734 reports list it as a suspect or interacting product, 2004–2026. Also reported as Amitriptyline /00002202/, Amitriptyline 10mg Tablets, Amitriptyline 25mg.
- 16,734
- reports as suspect product
- 0.1% of all reports · about 747 a year
- 1,208
- reports, 12 months to June 2026
- 1,358 in the 12 months before
- 90.9%
- marked serious by the reporter
- 57.4% across all reports
- 29.2%
- record death among outcomes, as reported
- 4,878 reports · not verified by FDA
16,734 adverse event reports received by FDA list amitriptyline, a generic name as a suspect or interacting product, from February 2004 to June 2026. A further 43,445 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 1,208 reports listed it, down 11% from 1,358 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 747 reports a year and 0.1% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded toxicity to various agents (16%), drug ineffective (12.8%) and completed suicide (9.8%). A report can list several reactions, so shares add to more than 100%; 1,884 different terms appear across these reports. Toxicity to various agents is recorded in 16% of these reports, against 0.8% of all reports in the database.
90.9% of the reports are marked serious by the reporter; 29.2% record death among the outcomes and 32.1% record hospitalisation, as reported. 36.9% of the reports came from other health professionals, and the largest patient age group is 45 to 64 (33%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Amitriptyline reports recording the termall reports in the database
- Toxicity to various agentspoisoning or toxic effect of one or more substances16%2,675
- Drug ineffectivethe medicine did not work as expected12.8%2,143
- Completed suicidedeath by suicide9.8%1,633
- Off label useused for a purpose or in a way not on the label8.5%1,420
- Drug interactionan interaction between medicines7.9%1,321
- Drug abusemisuse of a medicine5.9%988
- Overdosea dose above the recommended amount5.7%947
- Dizzinesslight-headedness or unsteadiness5.4%912
- Nauseafeeling sick5.3%888
- Painpain, site not specified5.2%862
- Hyperhidrosisexcessive sweating5%834
- Fatiguetiredness5%832
- Product use in unapproved indicationused for a purpose not on the label4.6%778
- Hypotensionlow blood pressure4.6%763
- Deaththe patient died; cause not stated by this term4.4%744
- Sedationdrowsiness from a medicine4.4%743
- Falla fall4.3%727
- Somnolencedrowsiness4.1%686
- Depressionlow mood4.1%685
- Constipationconstipation4%661
- Headachehead pain3.6%607
- Serotonin syndrometoo much serotonin activity, with agitation, fever and tremor3.6%605
- Intentional overdosea deliberate overdose3.5%594
- Dyspnoeashortness of breath3.4%569
- Cardiac arrestthe heart stopped3.2%543
- Vomitingbeing sick3.2%541
- Confusional stateconfusion3.2%532
- Nightmarenightmares3.2%530
- Malaisegeneral feeling of being unwell3.1%518
- Diarrhoealoose or frequent stools3.1%511
Top 30 of 1,884 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 37.1% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Depression | 899 | 5.4% |
| Migraine | 496 | 3% |
| Pain | 432 | 2.6% |
| Neuralgia | 416 | 2.5% |
| Insomnia | 310 | 1.9% |
| Headache | 107 | 0.6% |
The indication field is filled in by the reporter and is often blank; shares are of all 16,734 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Amitriptyline reports |
|---|---|---|
| Gabapentin | 3,088 | 18.5% |
| Pregabalin | 1,862 | 11.1% |
| Diazepam | 1,626 | 9.7% |
| Acetaminophen | 1,624 | 9.7% |
| Tramadol | 1,278 | 7.6% |
| Topiramate | 1,210 | 7.2% |
| Codeine | 1,129 | 6.7% |
| Duloxetine | 1,124 | 6.7% |
| Nortriptyline | 1,060 | 6.3% |
| Omeprazole | 1,055 | 6.3% |
Other products listed in reports where Amitriptyline is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Amitriptyline | All reports |
|---|---|---|
| Reports as suspect product | 16,734 | 20,646,523 |
| Share of that pool | — | 0.1% |
| Reports, latest 12 months | 1,208 | 1,332,454 |
| Marked serious | 90.9% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 292 | 91 |
| Hospitalisation recorded, per 1,000 reports | 321 | 213 |
| Consumer-filed share | 20% | 45.8% |
| Top term, share of reports | Toxicity to various agents 16% | 0.8% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Amitriptyline reports
How many adverse event reports has FDA received for Amitriptyline?
16,734 reports list Amitriptyline as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 1,208 of them arrived in the latest 12 months. Another 43,445 list it only as a concomitant medication.
What reactions are recorded in Amitriptyline reports?
toxicity to various agents (16%), drug ineffective (12.8%), completed suicide (9.8%), off label use (8.5%) and drug interaction (7.9%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Amitriptyline was responsible.
How serious are the reports?
90.9% are marked serious by the reporter. Among the outcomes recorded, 29.2% of reports include death and 32.1% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
other health professional (36.9%), physician (29.6%) and consumer or non-health professional (20%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Amitriptyline rising?
1,208 reports in the 12 months to June 2026, down 11% from 1,358 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Amitriptyline was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Amitriptyline?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Amitriptyline as a suspect or interacting product; reports listing it only as a concomitant medication (43,445) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.